# TRANSFORM-2 (NCT04468984)

> Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

No report yet. It can be ordered.

- Drugs tested: navitoclax plus ruxolitinib; navitoclax
- Indication: relapsed/refractory myelofibrosis

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04468984
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Myelofibrosis (MF)
- Interventions: Navitoclax; Ruxolitinib; Best Available Therapy (BAT)
- Enrollment: 330
- Primary outcome: Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)

## Indexed commentary on TRANSFORM-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 4
- Podcasts: 3
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=transform-2-nct04468984

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04468984", "email": "<work email>"}; the inbox owner confirms by the emailed link.